Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563322 | 0.83 | CHEK2 (0.86) | CHEK2KMT2AMEN1POLBTDP1 | |
| SCHEMBL3564516 | 0.80 | CHEK2 (0.71) | CHEK2KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3571725 | 0.80 | CHEK2 (0.68) | CHEK2KDM4ESMN1; SMN2GAARAB9A | |
| SCHEMBL3562499 | 0.79 | CHEK2 (0.68) | CHEK2KDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL3560900 | 0.79 | CHEK2 (0.68) | CHEK2KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL3571768 | 0.76 | CHEK2 (0.71) | CHEK2KDM4EMAPTSMN1; SMN2GAA | |
| SCHEMBL3574951 | 0.76 | CHEK2 (0.73) | CHEK2MAPTSMN1; SMN2POLBGAA | |
| SCHEMBL3568934 | 0.76 | CHEK2 (0.70) | CHEK2KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL28221694 | 0.75 | KMT2A (0.68) | KMT2AKDM4EMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL25248439 | 0.71 | KMT2A (0.68) | KMT2AKDM4EMAPTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726235-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1613313-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004093873-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-`4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-04 | — | — | WO | claimed |
| US-7687639-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | BW CONVERTING AB (SE) | 2006-11-09 | — | — | US | disclosed |
| US-7132440-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252793-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885KMT2A 4404/4885KDM4E 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.